Exactly....I think you'll find these distinctions are made because they address different 'markets' that attract different funding and revenue streams.
Don't over-analyse the table....management are doing their best to explain what they can whilst keeping 'in confidence' negotiations under their hat as per regulatory requirements..
The lack of detail on 'therapeutics' is a perfect example.
But....anyone who has followed TLX would understand the upside in that space.
Screening v monitoring, page-3
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.0¢ |
Change
-0.040(6.06%) |
Mkt cap ! $57.05M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 67.0¢ | 62.0¢ | $83.87K | 129.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | 61.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.5¢ | 739 | 1 |
View Market Depth
| Last trade - 15.48pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
62.5¢ |
Change
-0.040 ( 3.10 %) |
||||
| Open | High | Low | Volume | ||
| 66.0¢ | 66.5¢ | 62.5¢ | 7536 | ||
| Last updated 15.48pm 17/06/2024 ? | |||||
| IIQ (ASX) Chart |
